Concepedia

L.S. Chan

LC

Statistics

Publications

1

Citations

97

H-Index

1

Active since

2022

Affiliations

Nanjing University of Chinese Medicine(Current)

L.S. Chan is an author at Nanjing University of Chinese Medicine specializing in cancer therapeutics, radiation oncology, and hepatology.

Top concepts

Publications per year

2022–2022

1

Publications

1

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin, L.S. Chan, Shanzhi Gu et al. · Annals of Oncology · 2022 · 97 citations

, , +9

1–1 of 1